Latamoxef, also known as Moxalactam, is a broad-spectrum beta-lactam antibacterial agent belonging to the oxacephem class of antibiotics. It is an active pharmaceutical ingredient used in the development and manufacture of antibacterial pharmaceutical formulations.
Latamoxef inhibits bacterial cell-wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). This interferes with the final stages of peptidoglycan synthesis and results in bacterial cell-wall disruption and death.
Latamoxef is a semisynthetic oxacephem antibiotic structurally related to the cephalosporin family. It has the molecular formula C20H20N6O9S and a molecular weight of approximately 520.48 g/mol. The CAS Number is 64953-12-4.
Latamoxef is generally supplied as a white to off-white pharmaceutical-grade powder, commonly in a suitable salt form for pharmaceutical formulation.
Latamoxef exerts its antibacterial activity by binding to bacterial penicillin-binding proteins (PBPs). This inhibits transpeptidation and other processes required for peptidoglycan cross-linking in the bacterial cell wall.
The resulting weakening of the bacterial cell wall leads to osmotic instability and bacterial cell lysis.
Latamoxef has activity against a broad range of susceptible Gram-positive and Gram-negative bacteria. It has particularly important activity against many Gram-negative organisms and is relatively resistant to degradation by several bacterial beta-lactamases.
Susceptibility varies among organisms and geographical regions, and antimicrobial use should be based on approved labeling and appropriate susceptibility testing.
Latamoxef has been used for the treatment of serious bacterial infections involving susceptible organisms, including infections of the respiratory tract, urinary tract, intra-abdominal region, bloodstream and other sites, depending on approved indications.
Latamoxef API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, sterility/endotoxin attributes where applicable to the finished product, and other applicable quality characteristics.
HPLC and suitable spectroscopic methods may be used for identity, assay and purity testing. Acceptance criteria should be based on the applicable pharmacopoeial monograph, approved drug-substance specification and Certificate of Analysis.
Latamoxef should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage requirements should follow the approved manufacturer's specification.
Latamoxef API may be supplied for qualified pharmaceutical manufacturing, formulation development, research and analytical applications. Product specifications, Certificate of Analysis, packaging details and regulatory documentation should be confirmed according to the intended application.
Latamoxef API is available for pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details for their specific requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |